Rdh10a deficient embryos have decreased expression of RA signaling responsive genes. by Enrico D’Aniello (798447)

“…<p>(A-F) ISH for <i>cyp26a1</i>, <i>hoxb5b</i>, <i>and dhrs3a</i> expression in control sibling and Rdh10a deficient embryos. …”

Mean frequency of the cultural trait <i>T</i> in the population when <i>T</i> decreases fertility. by Laurel Fogarty (143721)

CC-1⁺ immunostained cell numbers decrease by 2 days after TBI and return to control levels by 5 weeks. by Krista A. Dent (709531)

“…Panels show contralateral (Contra) and ipsilateral (Ipsi) external capsule (EC) at (A,B) 2 days (2d), (C,D) 2 weeks (2w) and (E,F) 5 weeks (5w) (G) In the external capsule numbers of CC-1⁺ oligodendrocytes were decreased by 2d after injury, remained decreased at 2 weeks and returned to normal levels by 5 weeks. …”

Effect of 5-HTR blockade on cost-based motivation. by Yukiko Hori (299784)

PKC inhibition increases intracellular cAMP and PKC activation decreases intracellular cAMP levels. by Katie M. Lowther (427408)

As₂O₃ decreases myoblast growth. by Shing Hwa Liu (38213)

Downhill Running-Based Overtraining Protocol Improves Hepatic Insulin Signaling Pathway without Concomitant Decrease of Inflammatory Proteins - Fig 5 by Alisson L. da Rocha (804331)

Fig 5 - by Wardah K. Mustahsan (17484456)

Immunostaining patterns of 5-mC and 5-hmC in normal glandular epithelium and adenocarcinoma in situ (AIS). by Jobran M. Moshi (18405149)

“…Note the dramatic decrease in 5-hmC immunofluorescence in the AIS structures (gland 1 normal columnar epithelium, glands 2 and 3 containing AIS structures). …”

One-step growth cycle of CVB3 wild type and M1-M6 mutant viruses in HeLa cells. by Jawhar Gharbi (11492361)

Inhibition of ERK 1/2 decreases GM-CSF- and IL-3-responsive Eo/B CFU, but not IL-5-responsive colonies. by Pia Reece (589971)

Focal adhesion kinase phosphorylation levels within the optic nerve head decrease steadily after intraocular pressure elevation. by Shandiz Tehrani (3365900)

Hepatic irradiation decreases the proportion of DX5^–TRAIL⁺ lrNK cells for up to two months. by Ryosuke Nakano (4557097)

“…NK cells were divided into DX5^–TRAIL⁺ lrNK cells and DX5⁺TRAIL⁻ cNK cells. …”

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Pharmacologic blockade of 5LO decreases Aβ peptides levels and deposition in the 3×Tg mice via the γ-secretase pathway. by Jin Chu (358006)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects: